Overlapping Buprenorphine Initiation (in Opioid Physical Dependence)

• Status: Not yet recruiting
• Trial end date: 2021-08-01
• Target enrollment: 30
• Participant gender: All

Summary

This clinical trial aims to assess the tolerability and effectiveness of overlapping buprenorphine initiation and full agonist opioid discontinuation among patients on high-dose long-term full agonist opioid therapy who have opioid physical dependence.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Connecticut Healthcare System
• Treatments: Analgesics, Opioid; Buprenorphine

Criteria

Inclusion Criteria:

• 3 months or more of 50 mg morphine equivalent daily dose or more full agonist opioid therapy

• evaluated in a pain management or opioid reassessment clinic within the past 60 days

• interested in switching to buprenorphine from full agonist opioid therapy for pain

Exclusion Criteria:

• none